Secure Asset Management LLC Acquires Shares of 1,055 Zoetis Inc. (NYSE:ZTS)

Secure Asset Management LLC bought a new stake in shares of Zoetis Inc. (NYSE:ZTSFree Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 1,055 shares of the company’s stock, valued at approximately $208,000.

Several other hedge funds have also recently made changes to their positions in ZTS. Norges Bank purchased a new position in shares of Zoetis during the fourth quarter valued at approximately $745,861,000. Morgan Stanley grew its stake in Zoetis by 34.6% in the fourth quarter. Morgan Stanley now owns 10,872,704 shares of the company’s stock worth $1,593,395,000 after purchasing an additional 2,796,694 shares during the period. Moneta Group Investment Advisors LLC grew its stake in Zoetis by 124,281.9% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 2,332,160 shares of the company’s stock worth $341,778,000 after purchasing an additional 2,330,285 shares during the period. Arrowstreet Capital Limited Partnership grew its stake in Zoetis by 171.7% in the first quarter. Arrowstreet Capital Limited Partnership now owns 3,326,448 shares of the company’s stock worth $627,335,000 after purchasing an additional 2,102,306 shares during the period. Finally, Vaughan Nelson Investment Management L.P. purchased a new stake in Zoetis in the third quarter worth $176,219,000. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Stock Up 0.4 %

ZTS stock opened at $169.21 on Monday. Zoetis Inc. has a fifty-two week low of $151.03 and a fifty-two week high of $201.92. The business’s 50-day moving average is $185.10 and its two-hundred day moving average is $181.99. The company has a debt-to-equity ratio of 1.32, a quick ratio of 2.00 and a current ratio of 3.36. The company has a market cap of $77.39 billion, a price-to-earnings ratio of 33.37, a P/E/G ratio of 2.58 and a beta of 0.85.

Zoetis (NYSE:ZTSGet Free Report) last posted its earnings results on Tuesday, February 13th. The company reported $1.24 earnings per share for the quarter, missing analysts’ consensus estimates of $1.32 by ($0.08). Zoetis had a net margin of 27.43% and a return on equity of 51.25%. The firm had revenue of $2.21 billion during the quarter, compared to the consensus estimate of $2.19 billion. During the same period in the prior year, the company posted $1.15 EPS. The firm’s revenue was up 8.5% compared to the same quarter last year. As a group, analysts forecast that Zoetis Inc. will post 5.8 earnings per share for the current year.

Zoetis Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 4th. Stockholders of record on Friday, April 19th will be paid a $0.432 dividend. This represents a $1.73 annualized dividend and a dividend yield of 1.02%. The ex-dividend date of this dividend is Thursday, April 18th. Zoetis’s dividend payout ratio (DPR) is currently 34.12%.

Insider Transactions at Zoetis

In other news, EVP Roxanne Lagano sold 363 shares of the firm’s stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $197.74, for a total value of $71,779.62. Following the transaction, the executive vice president now owns 20,417 shares of the company’s stock, valued at $4,037,257.58. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold 2,209 shares of company stock valued at $408,453 over the last quarter. 0.15% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on ZTS shares. Barclays upped their price target on Zoetis from $255.00 to $260.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 14th. StockNews.com cut Zoetis from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 20th. Stifel Nicolaus increased their target price on Zoetis from $195.00 to $215.00 and gave the stock a “buy” rating in a research note on Friday, January 12th. BNP Paribas assumed coverage on Zoetis in a research note on Thursday, December 7th. They issued an “outperform” rating and a $237.00 target price on the stock. Finally, Piper Sandler increased their target price on Zoetis from $215.00 to $220.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 20th. Nine investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $224.33.

Get Our Latest Stock Report on Zoetis

Zoetis Company Profile

(Free Report)

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Featured Articles

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.